Mounjaro®
Starting from £179.99/mo
Start journey Learn moreInsulin is not a weight-loss medicine, and injecting it without a clinical reason is genuinely dangerous. If you have arrived here wondering whether insulin injections could help you lose weight, the short answer is no — and the longer answer explains why the confusion exists, what the licensed alternatives are, and how to access them safely. These are prescription-only medicines that require a clinical assessment before any prescriber can approve them.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people land on 'insulin injection for weight loss' after reading about GLP-1 medicines in the news. If you want a fuller picture of what that search term actually covers, our page on insulin injections for weight loss explains the confusion in detail. Mounjaro and Wegovy are injected once a week using pre-filled pens, so they look superficially like insulin pens. That visual similarity, combined with the fact that some GLP-1 medicines also treat type 2 diabetes, is enough to blur things in a Google search. It is a genuinely easy mistake to make, and there is no embarrassment in having made it.
Here is the distinction that matters. Insulin is a hormone your pancreas produces to move glucose out of the bloodstream and into cells. When someone without diabetes injects it, blood sugar drops dangerously low, a condition called hypoglycaemia. Symptoms range from shakiness and confusion to seizures and loss of consciousness. There is no therapeutic weight-loss effect. In fact, higher insulin levels tend to encourage the body to store energy as fat, which is the opposite of the goal. For anyone who wants to understand the specific risks in more depth, our page on insulin injection for weight loss side effects sets out exactly why this approach is dangerous.
The NHS medicines page for tirzepatide explains clearly how GLP-1 treatments work and who they are intended for, it is a useful starting point if you want the clinical picture in plain language. Insulin sits in an entirely different pharmacological category, with a different mechanism, different risks, and a different licensed purpose.
Tirzepatide (Mounjaro) and semaglutide (Wegovy) work by mimicking gut hormones that your body releases after eating. They slow the rate at which the stomach empties, signal to the brain that you are full, and help regulate blood sugar, all of which reduces appetite over time. Tirzepatide activates two receptors (GIP and GLP-1); semaglutide activates one. Both are given as a once-weekly subcutaneous injection, typically into the abdomen, thigh or upper arm.
The evidence base is substantial. In the SURMOUNT-1 trial, participants using tirzepatide at the highest dose lost an average of around 20–21% of body weight over 72 weeks, results detailed in the New England Journal of Medicine's published paper. Semaglutide produced around 15% average weight reduction over 68 weeks in the STEP 1 trial. Those figures come from closely monitored clinical settings alongside dietary and lifestyle support, they are not guarantees, and results vary between individuals.
Both medicines are licensed for adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. Eligibility is assessed by a prescriber who looks at your whole health picture, not the BMI number alone. You can read more about injections in the context of insulin resistance if that is part of your situation.
GLP-1 medicines have a well-characterised side-effect profile, dominated by gastrointestinal symptoms. Nausea is the most commonly reported, particularly in the first few weeks or after a dose increase. Vomiting, loose stools, constipation, and reflux also appear, the body adjusts to a slower gastric emptying rate, and for most people the discomfort settles within a couple of weeks. Vomiting after a weight-loss injection is something our prescribers discuss with patients regularly, and there are practical ways to manage it.
More serious but infrequent effects include acute pancreatitis. The MHRA issued a Drug Safety Update in January 2026 specifically flagging this risk for GLP-1 medicines: severe, persistent stomach pain that radiates to the back (with or without vomiting) warrants urgent medical attention. Gallbladder problems and signs of dehydration from prolonged vomiting are also worth knowing about before starting. Report any suspected side effects to the MHRA Yellow Card scheme, which exists precisely so regulators can monitor real-world safety data.
Insulin misuse carries a completely different and more immediately dangerous risk profile, hypoglycaemia, cardiac arrhythmia, and in severe cases death. It is not a comparable trade-off. The licensed weight-loss medicines are not risk-free, but they have been through rigorous clinical development and are monitored by the MHRA throughout their use in practice.
Tirzepatide and semaglutide are both prescription-only medicines. The only legal route to them in the UK is a prescription issued after a clinical assessment by a qualified prescriber. That assessment exists to protect you, it checks for contraindications, reviews your current medicines, considers your BMI and any relevant health conditions, and determines which treatment and which starting dose makes sense for your situation.
If you are curious about what current treatment costs look like, our weight-loss injection pricing page covers what is typically included in a legitimate private prescription. One thing worth knowing: a price that seems far below market is more often a red flag than a bargain. Counterfeit pens have been seized in large numbers by the MHRA, and some have been found to contain substances other than what was advertised.
Our weight-loss injection overview covers both Mounjaro and Wegovy side by side if you want to compare them before deciding. If you have already done your reading and want to take the next step, a conversation with our prescribers is the practical place to start. At nume, every consultation is read personally by a GPhC-registered Independent Prescriber, a real clinician, on the day you submit it. If treatment is clinically suitable, it is dispatched the same day for free next-working-day delivery.
Speak to our prescribers by starting your free consultation at our treatment page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.